Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
20/01/2026 16:05
Jan 20 (Reuters) - Phio Pharmaceuticals Corp PHIO.O: PHIO PHARMACEUTICALS CORP - ANNOUNCES KEY TUMOR RESPONSE DATA FROM PH-762 TRIAL - SEC FILING PHIO PHARMACEUTICALS CORP - 70% OVERALL RESPONSE RATE FOR SQUAMOUS CELL CARCINOMAS IN TRIAL - SEC FILING PHIO PHARMACEUTICALS CORP - FAVORABLE SAFETY AND TOLERABILITY AT ALL DOSE ESCALATIONS - SEC FILING PHIO PHARMACEUTICALS CORP: SAFETY DATA THROUGH EXTENDED FOLLOW-UP PERIOD IS EXPECTED TO BE REPORTED IN Q2 OF 2026 Source text: [ID:n0001437749-26-001500] Further company coverage: PHIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing